TENX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
17.7M
-5.6%
18.8M
+13.3%
16.6M
+0.8%
16.4M
-2.1%
16.8M
R&D
12.1M
-6.1%
12.8M
+11.4%
11.5M
+9.5%
10.5M
+2.1%
10.3M
SG&A
5.7M
-4.6%
5.9M
+17.9%
5.0M
-14.8%
5.9M
-8.8%
6.5M
Operating Income
-17728000
+5.6%
-18784000
-13.3%
-16573000
-0.8%
-16449000
+2.1%
-16806000
EBITDA
-17728000
+5.6%
-18784000
-13.3%
-16573000
-0.8%
-16449000
+2.1%
-16806000
Net Income
-16704000
+6.2%
-17803000
-13.3%
-15716000
-1.1%
-15540000
+1.7%
-15804000
EPS (Basic)
$-0.31
+11.4%
$-0.35
+0.0%
$-0.35
+7.9%
$-0.38
+5.0%
$-0.40
EPS (Diluted)
$-0.31
+11.4%
$-0.35
+0.0%
$-0.35
+7.9%
$-0.38
+5.0%
$-0.40
Shares (Diluted)
53.5M
+5.1%
50.9M
+12.5%
45.2M
+10.4%
41.0M
+3.1%
39.7M
Tenax Therapeutics (TENX) — Financials